Congenital absence of a pulmonary artery is a rare entity often followed by complications. Up to now only two patients have done well after revascularization of the affected lung. We have had the opportunity to operate upon the two youngest patients suffering from an absence of a right or left pulmonary artery. In both cases revascularization of the lung was achieved with the use of a PTFE graft. In the second case, a non previously described technique has been applied successfully. Both children have been doing well up to now. This experience has led us to believe that revascularization of the affected lung should be done even in very young patients and that pulmonary hypertension may regress.

Download full-text PDF

Source

Publication Analysis

Top Keywords

revascularization lung
12
absence pulmonary
8
pulmonary artery
8
[congenital unilateral
4
unilateral absence
4
pulmonary
4
pulmonary artery]
4
artery] congenital
4
congenital absence
4
artery rare
4

Similar Publications

Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization.

J Thorac Cardiovasc Surg

January 2025

Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:

View Article and Find Full Text PDF

Multisociety Endorsement of the 2024 European Guideline Recommendations on Coronary Revascularization.

Ann Thorac Surg

January 2025

Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:

View Article and Find Full Text PDF

Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors.

JACC CardioOncol

December 2024

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.

Background: Hormone therapies, including aromatase inhibitors and tamoxifen, are used with ovarian suppression to improve outcomes in premenopausal patients with breast cancer. Cardiovascular impacts of these treatments among premenopausal women are unknown.

Objectives: The aim of this study was to test the hypothesis that the use of aromatase inhibitors in combination with ovarian suppression, relative to tamoxifen, is associated with greater incident cardiovascular disease (CVD) risk in premenopausal breast cancer survivors.

View Article and Find Full Text PDF

Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization.

Eur J Cardiothorac Surg

December 2024

Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

View Article and Find Full Text PDF

Variations in Revascularization Strategies for Chronic Limb-Threatening Ischemia: A Nationwide Analysis of Medicare Beneficiaries.

JACC Cardiovasc Interv

December 2024

Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

Background: Recent data support both surgical-first and endovascular-first revascularization approaches for chronic limb-threatening ischemia (CLTI), but hospital-based practices are poorly described.

Objectives: This aim of this study was to characterize contemporary variations and outcomes associated with each strategy among U.S.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!